Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
Healthcare | Drug Manufacturers - General | USA
statements
IndexS&P 500 P/E- EPS (ttm)-0.10 Insider Own0.10% Shs Outstand2.26B Perf Week2.20%
Market Cap133.06B Forward P/E8.11 EPS next Y7.44 Insider Trans-8.52% Shs Float2.25B Perf Month-3.07%
Income-563.00M PEG- EPS next Q1.49 Inst Own76.00% Short Float0.64% Perf Quarter1.45%
Sales34.86B P/S3.82 EPS this Y-33.90% Inst Trans-1.92% Short Ratio1.45 Perf Half Y9.98%
Book/sh21.69 P/B2.78 EPS next Y18.58% ROA-0.50% Target Price73.50 Perf Year19.03%
Cash/sh9.81 P/C6.14 EPS next 5Y22.20% ROE-1.30% 52W Range45.76 - 68.34 Perf YTD-6.08%
Dividend1.80 P/FCF15.43 EPS past 5Y10.90% ROI5.50% 52W High-11.78% Beta0.69
Dividend %2.99% Quick Ratio1.40 Sales past 5Y10.50% Gross Margin69.90% 52W Low31.75% ATR1.19
Employees30000 Current Ratio1.50 Sales Q/Q61.50% Oper. Margin15.00% RSI (14)54.83 Volatility2.10% 2.12%
OptionableYes Debt/Eq0.95 EPS Q/Q-104.30% Profit Margin-1.60% Rel Volume1.04 Prev Close59.90
ShortableYes LT Debt/Eq0.85 EarningsNov 05 BMO Payout- Avg Volume9.93M Price60.29
Recom1.90 SMA201.53% SMA50-0.30% SMA200-0.45% Volume10,318,672 Change0.65%
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Sep-29-20 06:59AM  
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia
Business Wire
Sep-26-20 08:00AM  
Bristol-Myers Squibb Company (NYSE:BMY) Goes Ex-Dividend Soon
Simply Wall St.
Sep-25-20 09:27AM  
ROCE Insights For Bristol-Myers Squibb
Benzinga
05:16AM  
Patient Investors Will Stick With Very Cheap Bristol-Myers Squibb Stock
InvestorPlace
Sep-24-20 04:15PM  
Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial
Business Wire
Sep-23-20 01:28PM  
'Pandemic fatigue is hitting the nation': Expert
Yahoo Finance Video
Sep-22-20 04:22PM  
Bristol Myers, Bluebird Bio Blood Cancer Treatment Gets FDA Priority Review; BLUE Stock Up
Investor's Business Daily
01:20PM  
FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy
Motley Fool
06:59AM  
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
Business Wire
Sep-21-20 04:16PM  
Bristol Myers Squibb Completes Acquisition of Forbius
Business Wire
12:31PM  
Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting
Business Wire
12:30PM  
Opdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers
Business Wire
Sep-20-20 08:09AM  
3 Dividend Stocks to Buy on Sale
Motley Fool
Sep-19-20 12:30PM  
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
Business Wire
Sep-18-20 06:05PM  
Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study
Reuters
10:53AM  
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers
Zacks
07:17AM  
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Business Wire
Sep-17-20 04:16PM  
Bristol Myers Squibb to Announce Results for Third Quarter 2020 on November 5, 2020
Business Wire
03:50PM  
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Motley Fool
11:28AM  
A Unique Security at a 68% Discount to Fair Value
GuruFocus.com
06:59AM  
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddys
Business Wire
06:15AM  
Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Business Wire
Sep-15-20 12:27PM  
US government must rebuild trust in the FDA: top doctor
Yahoo Finance
12:09PM  
Gilead Is Buying Immunomedic. What the Bond Market Has to Say About the Deal.
Barrons.com
07:30AM  
Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE Cell Therapy Candidate
PR Newswire
06:59AM  
European Medicines Agency Validates Bristol Myers Squibbs Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural Mesothelioma
Business Wire
Sep-14-20 09:48AM  
The Zacks Analyst Blog Highlights: Facebook, McDonald's, Bristol-Myers Squibb, Netflix, and U.S. Bancorp
Zacks
Sep-12-20 08:30AM  
2 Companies That Raised Their Dividends This Week
Barrons.com
Sep-11-20 02:39PM  
Top Research Reports for Facebook, McDonalds & Bristol-Myers
Zacks
10:20AM  
U.S. Drug Stocks Look Cheap. Heres Why, According to One Analyst.
Barrons.com
Sep-10-20 06:22PM  
Bristol Myers Squibb Declares Fresh Dividend; Yield Is 3.1%
Motley Fool
04:47PM  
NIH launches two trials to test blood thinners in COVID-19 patients
Reuters
04:15PM  
Bristol Myers Squibb Announces Quarterly Dividend for Third Quarter 2020
Business Wire
06:59AM  
Bristol Myers Squibb to Participate in Morgan Stanleys 18th Annual Global Healthcare Virtual Conference
Business Wire
Sep-09-20 08:00PM  
Market Digest: BMY
Argus Research
08:00PM  
Analyst Report: Bristol-Myers Squibb Co.
Argus Research
05:21AM  
2 Healthcare Stocks That Are Better Value Buys Than Apple
Motley Fool
Sep-08-20 07:23PM  
Analyst Report: Bristol-Myers Squibb Company
Morningstar Research
04:15PM  
COVID-19 vaccine safety pledge will make 'huge difference': Doctor
Yahoo Finance Video
06:59AM  
Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need
Business Wire
Sep-07-20 08:00AM  
What We Learned About Bristol-Myers Squibb's (NYSE:BMY) CEO Pay
Simply Wall St.
Sep-05-20 11:32AM  
Why Is Bristol Myers (BMY) Down 2.3% Since Last Earnings Report?
Zacks
Sep-03-20 07:00AM  
Pfizer Rises On Coronavirus Vaccine Supply Deals But Is PFE Stock A Buy?
Investor's Business Daily
Sep-02-20 10:33AM  
Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg
Zacks
06:59AM  
Bristol Myers Squibb to Participate in Citis 15th Annual BioPharma Virtual Conference
Business Wire
02:31AM  
Bristol Myers Scores FDA Nod For Acute Myeloid Leukemia Treatment
SmarterAnalyst
Sep-01-20 11:42PM  
Bristol Myers Squibb Wins FDA Approval for Leukemia Drug
Motley Fool
12:50PM  
U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
Business Wire
09:00AM  
Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
Business Wire
06:50AM  
2 Embarrassingly Cheap Dividend Stocks
Motley Fool
Aug-27-20 06:47AM  
Got $1,000? Invest in This Rock-Solid Dividend Stock
Motley Fool
Aug-26-20 04:06PM  
Shares of Bristol-Myers Have Tremendous Potential
GuruFocus.com
09:09AM  
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
Zacks
07:00AM  
Bristol Myers Is Launching A New MS Drug But Is BMY Stock A Buy?
Investor's Business Daily
Aug-25-20 09:47PM  
Hedge Funds Cant Stop Buying Bristol Myers Squibb (BMY) Shares
Insider Monkey
10:52AM  
Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline
Zacks
06:59AM  
Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Business Wire
Aug-24-20 06:59AM  
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Business Wire
Aug-21-20 11:09AM  
5 New Stocks That Are Hedge Funds Favorites
Barrons.com
Aug-20-20 09:40AM  
Drugmakers slash prices to obtain China's bulk-buy contracts -state media
Reuters
06:08AM  
3 Biotech Stocks You Can Buy and Hold for the Next Decade
Motley Fool
Aug-19-20 12:00PM  
Two Surprising FDA Rejections Raise Alarms for Biotech Investors
Bloomberg
06:30AM  
My Top Pharma Stock to Buy in the Next Market Crash
Motley Fool
Aug-18-20 06:40PM  
Latest Innovent Deal Gives Eli Lilly Drug Rights Outside China
GuruFocus.com
05:04PM  
Bristol Myers & Dragonfly Team Up for Immunotherapy Program
Zacks
01:53PM  
David Rolfe's Top 5 2nd-Quarter Trades
GuruFocus.com
Aug-17-20 06:15PM  
Bristol-myers Squibb Company (BMY) EVP, General Counsel Sandra Leung Sold $8.9 million of Shares
GuruFocus.com
08:33AM  
3 New Drug Launches of 2020 -- and the Stocks That Could Win Big
Motley Fool
06:59AM  
Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonflys IL-12 Investigational Immunotherapy Program
Business Wire
Aug-12-20 03:25PM  
Samsung Biologics Leaps to 3rd Among Most Valuable South Korean Companies
GuruFocus.com
12:23PM  
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
Zacks
08:41AM  
Bristol-Myers Squibb Invests $300 Million to Diversify Trials
TheStreet.com
06:59AM  
Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts
Business Wire
Aug-11-20 09:48AM  
Dow Jones Today Tops 28,000, Stocks Mixed, Travel Issues Rally On 'Sputnik V'; 5 Blue Chips In Bases
Investor's Business Daily
Aug-10-20 03:54AM  
Bristol Myers Reports Significant Survival Improvement For Rare Lung Cancer
SmarterAnalyst
Aug-08-20 07:00AM  
Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
Business Wire
Aug-07-20 10:42AM  
Analyzing Bristol-Myers Squibb's Unusual Options Activity
Benzinga
Aug-06-20 04:14PM  
US STOCKS-Wall Street gains as markets look to aid package, Nasdaq closes above 11,000
Reuters
04:10PM  
Bristol Myers Squibb Earnings Top After Drug Giant Wins Key Patent Fight
Investor's Business Daily
04:06PM  
Stock market news live updates: Nasdaq closes above 11,000 for the first time ever as Big Tech rallies
Yahoo Finance
04:00PM  
US STOCKS-Wall Street gains as markets look to aid package, Nasdaq closes above 11,000
Reuters
02:34PM  
US STOCKS-Wall Street gains as markets await aid package, U.S. jobs data
Reuters
01:42PM  
Early Sales of Eli Lilly's Migraine Drug Disappoint
GuruFocus.com
01:25PM  
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates
Zacks
01:11PM  
US STOCKS-S&P 500 flat as Congress wrangles over stimulus
Reuters
12:54PM  
Kahn Brothers Cuts Merck & Co., Hologic
GuruFocus.com
12:22PM  
Bristol-Myers Squibb Boosts Outlook Now That Patients Are Coming Back
Barrons.com
11:56AM  
A Look Into Bristol-Myers Squibb's Debt
Benzinga
11:55AM  
US STOCKS-Wall St struggles for direction as Congress wrangles over stimulus
Reuters
10:37AM  
US STOCKS-Wall Street flat, awaits fresh fiscal aid package
Reuters
10:17AM  
Back to Back Wins for Bristol-Myers, and Here's How I'd Trade It
TheStreet.com
09:59AM  
Dow Jones Today, Stocks Open Lower After Jobless Data; Health Sector Rallies Behind Bristol Myers, Bausch Health
Investor's Business Daily
09:57AM  
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up
Zacks
09:33AM  
Bristol-Myers Squibb Beats Q2 Earnings Forecast, Lifts 2020 Profit Outlook
TheStreet.com
09:01AM  
US STOCKS-Wall St set for subdued open as investors await fiscal aid
Reuters
07:49AM  
Bristol-Myers Squibb's stock is up on better-than-expected earnings
MarketWatch
07:01AM  
Bristol Myers lifts annual profit view on hopes of pickup in patient visits
Reuters
06:59AM  
Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors
Reuters
06:59AM  
Bristol Myers Squibb Reports Second Quarter 2020 Financial Results
Business Wire
06:43AM  
US STOCKS-Futures muted ahead of weekly unemployment claims data
Reuters
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in the following therapeutic classes: hematology, oncology, cardiovascular, and immunology. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, and Ubiquigent Limited; clinical collaboration agreement with NeoImmuneTech, Inc.; and partnership with Astrazeneca Plc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Santiago Karen MurphySVP & ControllerSep 01Option Exercise0.0064208,390Sep 02 04:33 PM
Caforio GiovanniChairman and CEOAug 31Sale62.7039,8402,497,968445,584Sep 02 04:34 PM
Eid JosephSVP,Head Glob. Medical AffairsAug 17Sale64.005,327340,9282,534Aug 19 06:15 PM
LEUNG SANDRAEVP, General CounselAug 13Sale63.24141,4208,943,401432,744Aug 17 04:55 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,402080,698Aug 04 04:43 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,35609,356Jul 02 04:56 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,06908,115Jul 02 04:54 PM
Paliwal Dinesh CDirectorJun 15Buy54.509,174499,98322,109Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0055808,650Jun 16 05:16 PM
Haller Julia ADirectorJun 14Option Exercise0.0055806,819Jun 16 05:15 PM
Haller Julia ADirectorJun 13Option Exercise0.0090306,261Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0090308,092Jun 16 05:16 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,15408,599Jun 09 07:15 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94905,358Jun 05 04:39 PM
BONNEY MICHAEL WDirectorJun 03Option Exercise0.002,94907,189Jun 05 04:40 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 22Sale61.013,200195,23216,086May 26 05:17 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 19Sale62.6825,0001,567,00026,777May 21 05:22 PM
VESSEY RUPERTEVP, Research & Early Dev.May 01Option Exercise0.0010,707059,050May 05 04:49 PM
AHMED NADIMEVP and President, HematologyMay 01Option Exercise0.002,908027,463May 05 04:49 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0030,519058,379Mar 12 06:18 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,8060152,400Mar 12 06:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0031,169058,421Mar 12 06:17 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.005,06307,778Mar 12 06:17 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0051,5980588,175Mar 12 06:15 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.001,57106,652Mar 12 06:13 PM
Elicker John EEVP, Investor RelationsMar 10Option Exercise0.0018,407075,102Mar 12 06:14 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00211,7960544,032Mar 12 06:11 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,007020,091Mar 12 06:12 PM
Bancroft Charles AEVP, Head of IntegrationMar 10Option Exercise0.0071,8680153,637Mar 12 06:11 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0021,426026,091Mar 12 06:11 PM
Elicker John EEVP, Investor RelationsMar 04Sale61.0115,805964,26358,666Mar 06 05:20 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Option Exercise51.6993,4684,831,452132,651Mar 04 06:19 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Sale60.5984,3085,108,22248,343Mar 04 06:19 PM
AHMED NADIMPresident, HematologyMar 01Option Exercise0.0017,204033,028Mar 03 08:04 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579044,766Mar 03 08:04 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 01Option Exercise0.0023,349048,106Mar 03 08:05 PM
AHMED NADIMPresident, HematologyFeb 04Option Exercise0.002,076016,895Feb 06 08:48 PM
VESSEY RUPERTPres., Research & Early Dev.Feb 04Option Exercise0.003,592025,920Feb 06 08:49 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0012,373026,281Jan 03 07:00 PM
VESSEY RUPERTPres., Research & Early Dev.Dec 31Option Exercise0.0016,060030,778Jan 03 07:00 PM
Dubow AdamChief Compliance & Ethics OffiDec 05Sale58.811,740102,32915,749Dec 09 04:44 PM
BONNEY MICHAEL WDirectorDec 04Buy58.90885,1837,189Jun 09 07:16 PM
Eid JosephSVPHead Global Medical AffairsDec 01Option Exercise0.002,82504,995Dec 03 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyNov 05Sale56.5625,0001,414,00031,963Nov 06 04:54 PM
Elicker John ESVP, Public Affairs & IRNov 05Sale56.6615,000849,90074,471Nov 06 04:54 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.0059206,417Oct 03 04:46 PM
open in yahoo | open in reuters | open in google